Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma
Published version of a preprint
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
PURPOSE: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest. PATIENTS AND METHODS: = 3) cells. Core needle biopsy was performed on tumor samples collected from diffuse large B-cell lymphoma patients on Day -6 (1 day before lymphodepletion) and on Day 11 after CAR T-cell infusion when adequate CAR T-cell expansion was detected. RESULTS: The overall response rate was 100%, with 6 of 9 (66.7%) evaluable patients achieving complete remission. The most common adverse events of grade 3 or higher were neutropenia (10/10, 100%), anemia (3/10, 30%), thrombocytopenia (3/10, 30%), and hypofibrinogenemia (2/10, 20%). Grade 1 cytokine release syndrome occurred in all patients and grade 3 neurotoxicity in 1 patient. The average peak levels of peripheral blood CAR T cells and cytokines were similar in 3 different dose levels, but CAR T cells were significantly higher in patients achieved complete remission on Day 29. Meanwhile, RNA sequencing identified gene expression signatures differentially enriched in complete and partial remission patients. Increased tumor-associated macrophage infiltration was negatively associated with remission status. CONCLUSIONS: JWCAR029 was effective and safe in treating refractory B-NHL. The composition of the tumor microenvironment has a potential impact in CAR T therapy response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, macrophages in the TME have been associated with relapse in 2 recently reported clinical trials of CD19 CAR T cells in LBCL.46,47”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [46]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“Tomimick the negative regulation of TAMswithM2phenotype macrophages on tumor-infiltrating T cells in vitro, we isolated human CD14þ monocytes from healthy donors and differentiated them intoM2macrophages, which have the same phenotype of TAMs as reported previously (24).”
ResultAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · cited 4×
“In this phase I, first-in human study of JWCAR029, the CR rate was 66.7%, which is consistent with results from the ZUMA-1, JULIET, and TRANSCEND studies.”
BackgroundInfluentialFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“9 concepts in the diagnosis and management of cytokine release syndrome (13).”
BackgroundCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 2×
“Aswe know, TAMs play an important role in the immune response (31).”
Background
Cited by
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“However, despite extensive research, the efficacy of CAR-T cell therapy on controlling solid tumors is limited effects due to the influence of TME (Yu et al., 2017; Li et al., 2018d; Yan et al., 2019).”
BackgroundJain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 175
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 154
Self-citation
Metadata
- Authors
- Yan, Z.-X., Li, L., Wang, W., OuYang, B.-S., Cheng, S., Wang, L., Wu, W., Xu, P.-P., Muftuoglu, M., Hao, M., Yang, S., Zhang, M.-C., Zheng, Z., Li, J., & Zhao, W.-L.
- Affiliations
- Shanghai Jiao Tong University (CN)
- 2JW Therapeutics, Shanghai, China.
- 3Department of Pathology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 5Department of Leukemia, University of Texas - MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Zhao, Wei-Li
- Venue
- Clinical Cancer Research
- Published
- 2019-12-01
- Volume
- 25
- Issue
- 23
- Pages
- 6995-7003
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2969586911
- Cited by
- 115
- References
- 34
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 21 · 2021: 13 · 2020: 14
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81520108003, 81830007, 81600155, 81670716)
- Chang Jiang Scholars Program, Shanghai Commission of Science and Technology (16JC1405800)
- Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (20152206, 20152208)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CD19 CAR T cells, CAR T-cell therapy, B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, tumor microenvironment, tumor-associated macrophages, dose escalation, complete remission, cytokine release syndrome, CAR-T cell expansion, gene expression signatures, lymphocyte depletion
- MeSH terms
- Adult, Antibodies, Monoclonal, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Immunotherapy, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Immunotherapy, Adoptive, Lymphoma, B-Cell, Salvage Therapy, Antigens, CD19, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0101
- The paper
- Yan, Z.-X., Li, L., Wang, W., OuYang, B.-S., Cheng, S., Wang, L., Wu, W., Xu, P.-P., Muftuoglu, M., Hao, M., Yang, S., Zhang, M.-C., Zheng, Z., Li, J., & Zhao, W.-L. (2019). Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.